

Application No. 09/211,715  
Reply to Advisory Action of July 2, 2003

September 10, 2003  
S&L File No. P26,835-D USA

**REMARKS**

Claims 7 to 11 and 20 to 23 and 25 remain in this application.

Applicants wish to thank the examiner for her acknowledgment in the Advisory Action of July 2, 2003 that claims 7 to 10 and 20 to 23 and 25 are "allowable because the claims are free of the recited prior art."

With regard to the Examiner's rejection of claim 11, under 35 U.S.C. § 112, second paragraph, for the recitation of "[Arg-OH]," Applicants have amended claim 11 to more clearly identify the C-terminal residue of the amino acid Arginine, "Arg-COOH."

Applicants have amended also claims 8 and 11 to delete duplicative members in the Markush groups of the claims. Currently amended claim 8 lists each of compounds Ac-pAph-Chg-Arg-Cys (CH<sub>2</sub>COOH) -Pro-NH<sub>2</sub>; (Alloc) -pAph-Chg-Arg-Leu-Pro-NH<sub>2</sub>; Ac-pAph-Chg-Arg-N [1(1,3-dicarboxy) propyl)] Gly-Pro-NH<sub>2</sub>; and (Benzoyl) - Phe (pNH<sub>2</sub>) -Chg-Arg-Leu-Pro-NH<sub>2</sub> once instead of twice. Currently amended claim 11 lists each of compounds Ac-pAph-Chg-Arg-NH<sub>2</sub> and Ac-pAph-Chg-PalMe(3) -NH- (4-methoxycarbonyl-cyclohexyl) methyl once instead of twice.

Enclosed herewith are the following documents: (A) a Revocation of Power of Attorney, dated August 7, 2003, and (B) a Copy of a Reply of May 7, 2003. The Revocation of (A) is submitted with a new Power of Attorney and Statement Under

Application No. 09/211,715  
Reply to Advisory Action of July 2, 2003

September 10, 2003  
S&L File No. P26,835-D USA

37 CFR 3.73(b); and the Copy of (B) is submitted in response to a request by the Examiner during a telephone conference of August 5, 2003.

In light of the Amendments and Remarks herein, Applicants submit that the claims are now in condition for allowance and respectfully request that a timely Notice of Allowance be issued in this case. The Examiner is invited to telephone the undersigned with any questions in regard to this application, and the Commissioner is authorized hereby to charge any additional fees associated with this communication to Deposit Account No. 19-5425.

Respectfully submitted,

September 10, 2003  
Date

Christopher P. Dahling  
Christopher P. Dahling  
Registration No. 51,140  
Synnestvedt & Lechner LLP  
2600 Aramark Tower  
1101 Market Street  
Philadelphia, PA 19107-2950

Telephone 215-923-4466  
Facsimile 215-923-2189  
Email [CDahling@synnleach.com](mailto:CDahling@synnleach.com)

CPD  
Enclosures

M:\CDahling\Aventis Pharma Deutschland GmbH\P26,835-D-USA\Amendment After Final Action.3.wpd